Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

TAMOXIFEN CITRATE

All products: general benefit

Other products in the same Health Canada class (L02B, L02BA) — coverage varies; not interchangeable

  • Fulvestrant (Faslodex): general benefit
  • Abiraterone (Zytiga): general benefit
  • Anastrozole (Arimidex): general benefit
  • Bicalutamide (Casodex): general benefit, Not a benefit
  • Degarelix (Firmagon): general benefit
  • Exemestane (Aromasin): general benefit

3 more in the class list below

Apo-Tamox · DIN 00812390 · 20mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Tamox · DIN 00812390 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 1989-12-31 · brand APO-TAMOX TAB 20MG · ATC L02BA01 TAMOXIFEN · form Tablet · route Oral · ingredients TAMOXIFEN (TAMOXIFEN CITRATE) 20 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Tamox: Formulary list price $0.3500/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3500 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10762 · Verify on the e-Formulary ↗ (DIN 00812390)

Source record
DIN 00812390: Apo-Tamox Raw flags: sec3=Y Item: 100000056; group id 185; item number 0335; lccId None; manufacturer id APX Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $0.3500; ministry $0.3500 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00812390 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10762
Interchangeable products
Nolvadex D · DIN 02048485 · not recorded Tamofen · DIN 01926632 · not recorded Teva-Tamoxifen · DIN 00851973 · $0.3500
Shortage status: resolved shortage (ended 2024-07-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00812390
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered

Matched class: 10:00 ANTINEOPLASTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, ANASTROZOLE, BUSERELIN ACETATE, BUSULFAN, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, IMATINIB MESYLATE, LETROZOLE, LEUPROLIDE ACETATE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE, TRIPTORELIN PAMOATE Some products covered without a code (check the product listing): BICALUTAMIDE, CYCLOPHOSPHAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, VINCRISTINE SULFATE 10:00 ANTINEOPLASTIC AGENTS

FULVESTRANT

· 6 products · General benefit · strengths: 50mg/mL · Inj Sol

ABIRATERONE ACETATE

· 18 products · General benefit · strengths: 250mg, 500mg · Tab

ANASTROZOLE

· 17 products · General benefit · strengths: 1mg · Tab

BICALUTAMIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 50mg · Tab

DEGARELIX ACETATE

· 2 products · General benefit · strengths: 80mg, 120mg · Pd for Inj-Vial Pk

EXEMESTANE

· 3 products · General benefit · strengths: 25mg · Tab

FLUTAMIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 250mg · Tab

LETROZOLE

· 20 products · General benefit · strengths: 2.5mg · Tab

ENZALUTAMIDE

· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 40mg · Cap

ALTRETAMINE

· 1 products · General benefit · strengths: 50mg · Cap

BUSERELIN ACETATE

· 4 products · General benefit · strengths: 6.3mg, 9.45mg, 1mg/mL · Implant Kit, Inj Sol-5.5mL Pk, Nas Sp-10mL Pk

BUSULFAN

· 1 products · General benefit · strengths: 2mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 10:00 and 34 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS APO-TAMOX (tamoxifen tablets) is indicated for: • the adjuvant treatment of early breast cancer in women with estrogen receptor positive tumours. • the treatment of women with hormone responsive locally advanced/ metastatic breast cancer. 1.1 Pediatrics Pediatrics (< 18 years of age): the use of APO-TAMOX is not recommended in children, as safety and efficacy have not been established. https://pdf.hres.ca/dpd_pm/00081612.PDF PM date: OCT 17, 1989 Source product: APO-TAMOX TAB 20MG; DIN 00812390; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.